c-GMP compliance of C-stem, an IPSc based cell therapies production technology

Informations projet

C-stemGMP

N° de convention de subvention: 881113

DOI

10.3030/881113

Projet clôturé

Date de signature de la CE 28 Novembre 2019

Date de début 1 Novembre 2019

Date de fin 31 Octobre 2021

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 3 382 855,00

Contribution de l’UE

€ 2 367 998,00

Coordonné par

TREEFROG THERAPEUTICS
France

Periodic Reporting for period 2 - C-stemGMP (c-GMP compliance of C-stem, an IPSc based cell therapies production technology)

Période du rapport: 2020-11-01 au 2021-10-31

Résumé du contexte et des objectifs généraux du projet

TreeFrog Therapeutics aims at providing access to cell therapies for millions of patients. The company has developed C-Stem, a high-throughput cell encapsulation technology allowing the mass-production and differentiation of stem cells in industrial bioreactors.
The european program, started in November 2019, is a global development plan including : Development of a cGMP encapsulation device, global Gmp validation of C-stem technology and deployment of Treefrog's co-development strategy with top therapeutic initiatives.
Today, cell therapy industry has no solution to insure safe and scalable production of its therapeutic cells. The technologies on the market today are either poorly reproducible or very limited in terms of scaling up. Some big initiatives like Resilience in the United states are now in line to develop production capacities and identify technologies that will unlock cell therapies market. In this perfect momentum, Treefrog is accelerating its development with the help of European commission.
The program must demonstrate that Treefrog's technology is fully adapted to cell therapy requirements and can be deploy in partnership with biotech and Pharmaceutical groups to accellerate availability of cell therapy products for patients.
Cellular therapy drugs represent a hope for cure for hundreds of millions of people around the world.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Since the start of the project, Treefrog has made spectacular advances in demonstrating its technology on an industrial scale. With the support of Invetech, the company developed a functional and fully integrated encapsulator prototype and deployed it in its laboratory for the production of 5 types of micro-tissues. The company has also internalized the production of microfluidic glass chips and validated the use of GMP compatible compounds throughout its process. The company has also started the deployment of its technologies by contracting with international groups to test its technology in major indications. The company, which is preparing a fundraising of € 50M for 2021, is perfectly positioned to become the leading biotech in Europe and a gold-standard technology at world level in the field of cell therapies.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Treefrog recently performed a comparative study of the quantitative and qualitative results of induced stem cell production in C-stem. The study was carried out using the technical results of the European project. The results of this study demonstrate a yield 5 times higher, a maintenance at an exceptional level of the pluripotency of the cells and an effective control of the mutations observed in the other methods of production (2D, aggregates). Treefrog's goal in 2021 is to consolidate its results on a scale never reached by the industry and to start 3 new collaborative programs. Until the end of the program, Treefrog should be able to propose to its clients a fully GMP compatible solution to perform their clinical studies.

Encapsulation device